About the Company
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NGM News
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Investors are always looking for stocks that are poised to beat at earnings season and NGM Biopharmaceuticals, Inc. NGM may be one such company. The firm has earnings coming up pretty soon, and events ...
NGM Biopharmaceuticals: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — NGM Biopharmaceuticals Inc. (NGM) on Monday reported a loss of $27.7 million in its fourth quarter. On a per-share basis ...
How a VC and a biotech founder plan to create a new biotech model
Jin-Long Chen knows the biotech cycle of life, maybe too well. Chen last year left NGM Biopharmaceuticals Inc. — the company he founded in 2007 and most recently served as chief scientific ...
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM ... One other stock from the same industry, Aadi Bioscience, Inc. (AADI), is yet to report results for the quarter ended December 2023. The results are expected ...
NGM Biopharmaceuticals Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NGM Biopharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...